171 results
8-K
EX-99.1
NUWE
Nuwellis Inc
7 May 24
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
11:02am
ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated
8-K
EX-99.1
NUWE
Nuwellis Inc
30 Apr 24
Nuwellis Announces Pricing of $2.7 Million Public Offering
6:25pm
related to the offering, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable
8-K
EX-99.2
NUWE
Nuwellis Inc
30 Apr 24
Nuwellis Announces Pricing of $2.7 Million Public Offering
6:25pm
of customary closing conditions related to the offering, those risks associated with our ability to execute on our commercialization strategy, the possibility
424B4
NUWE
Nuwellis Inc
29 Apr 24
Prospectus supplement with pricing info
4:58pm
, including our clinical and product development strategy,
or our competitors;
regulatory developments, disclosure regarding completed, ongoing
8-K
py55dsviegu frydu3kw
26 Mar 24
Other Events
5:00pm
8-K
EX-99.1
wkjtie1
6 Mar 24
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
12:02pm
8-K
EX-99.1
i0miko
6 Feb 24
Other Events
9:07am
8-K/A
EX-99.1
bfxbfkio0znhm71
9 Jan 24
Regulation FD Disclosure
5:30pm
8-K
EX-99.1
kjxvbjs5i 2ck8zz
8 Jan 24
Regulation FD Disclosure
9:24am
8-K
EX-99.1
456e58bp8w
7 Nov 23
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
8:15am
8-K
EX-99.1
0hfzt3vl9bgexp17w
1 Nov 23
Nuwellis Announces Board of Directors Transition
4:15pm
8-K
EX-99.2
b75e4og4zvnyd072 fin
17 Oct 23
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
4:30pm